Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-iNK 003
- Development stage
- Preclinical
- Lead developer
- ThinkingBiomed
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR-iNK 003 is an early-stage, induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by ThinkingBiomed. The candidate is engineered to express a chimeric antigen receptor (CAR) to recognize tumor-associated antigens and mediate cytotoxic killing of malignant cells. While the specific antigen target has not been publicly disclosed, the program is part of a pipeline targeting solid tumors and hematological malignancies, including lung cancer, liver cancer, colorectal cancer, and B-cell lymphoma. As of 2024, CAR-iNK 003 is in the early research phase of development.
- Other names
- CAR-iNK 003CAR-iNK003CAR-iNK-003
02
Targets
Beyond the preview
Go deeper on CAR-iNK 003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-iNK 003.